Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Zai Lab Starts Phase III China Trial of PARP Inhibitor

publication date: Jun 29, 2018

Zai Lab of Shanghai has dosed the first patient in a China Phase III registration trial of ZL-2306 (niraparib) as a first-line maintenance therapy for platinum-responsive ovarian cancer. Niraparib is an oral, once-daily PARP 1/2 inhibitor that Zai believes could be a first-in-class Category 1 drug in China for treating multiple solid tumor types. Zai also expects to begin a Phase III trial of niraparib for small cell lung cancer by mid-2018. More details....

Stock Symbol: (NSDQ: ZLAB)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.